Introduction: The aim of this study was to investigate demographic, anatomical, angiographic, and functional parameters in patients suffering from polypoidal choroidal vasculopathy (PCV). Methods: Sixty eyes of 60 patients with a definite diagnosis of treatment-naïve exudative unilateral PCV were evaluated in this retrospective study. Fellow eyes and age-matched healthy subjects were enrolled as comparison. All subjects underwent complete ophthalmic evaluation with multimodal imaging assessment, including spectral-domain optical coherence tomography (OCT) and OCT angiography. Main outcome measures in the comparison analysis were central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and choroidal vascularity index (CVI), whereas outcome measures for correlation analyses were best corrected visual acuity (BCVA), intraretinal fluid and subretinal fluid (SRF) presence, SRF thickness, vascularized pigmented epithelial detachment height, and PCV outer retina to choriocapillaris flow area. Results: CVI was significantly higher in affected and fellow eyes if compared with the healthy ones (p = 0.049; p = 0.003). Subfoveal choroid resulted to be thicker in the diseased eyes when compared with healthy ones (p = 0.002). A negative correlation was assessed between age and SFCT, CMT, and BCVA. In addition, a significant association between male gender and anatomical and functional parameters has been found with male prevalence at baseline in cases. No association between systemic conditions and PCV features was found. Conclusions: Patients with unilateral PCV show choroidal changes in terms of higher values of CVI, also in fellow eyes, that were negatively related with age. In our cohort of patients, males showed the poorest diagnosis with a baseline lower BCVA and higher CMT when compared with females. PCV was not associated with any systemic condition.

1.
Cheung
CMG
,
Lai
TYY
,
Ruamviboonsuk
P
,
Chen
SJ
,
Chen
Y
,
Freund
KB
, et al
.
Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management
.
Ophthalmology
.
2018
;
125
(
5
):
708
24
.
2.
Koh
A
,
Lai
TYY
,
Takahashi
K
,
Wong
TY
,
Chen
LJ
,
Ruamviboonsuk
P
, et al
.
Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial
.
JAMA Ophthalmol
.
2017
;
135
(
11
):
1206
.
3.
Lafaut
BA
,
Aisenbrey
S
,
Heimann
K
,
Van Den Broecke
C
,
Bartz-Schmidt
KU
.
Polypoidal choroidal vasculopathy pattern in age-related macular degeneration
.
Retina
.
2000
;
20
(
6
):
650
.
4.
Subhi
Y
,
Nielsen
MK
,
Molbech
CR
,
Oishi
A
,
Singh
A
,
Nissen
MH
, et al
.
Polypoidal choroidal vasculopathy associate with diminished regulatory T cells that are polarized into a T helper 2-like phenotype
.
Invest Ophthalmol Vis Sci
.
2019
;
60
(
7
):
2583
90
.
5.
Lee
WK
,
Baek
J
,
Dansingani
KK
,
Lee
JH
,
Freund
KB
.
Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness
.
Retina
.
2016
;
36
(
Suppl 1
):
S73
82
.
6.
Lorentzen
TD
,
Subhi
Y
,
Sørensen
TL
.
Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naïve exudative age-related macular degeneration
.
Acta Ophthalmol
.
2018
;
96
(
5
):
475
80
.
7.
Lorentzen
T
,
Subhi
Y
,
Tl
S
.
Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration
.
Retina
.
2017
;
1
.
8.
Corvi
F
,
Chandra
S
,
Invernizzi
A
,
Pace
L
,
Viola
F
,
Sivaprasad
S
, et al
.
Multimodal imaging comparison of polypoidal choroidal vasculopathy between asian and caucasian populations
.
Am J Ophthalmol
.
2022
;
234
:
108
16
.
9.
Jordan-Yu
JM
,
Teo
K
,
Fan
Q
,
Gana
JC
,
Leopando
AK
,
Nunes
S
, et al
.
T and genetic variations between Asian and Caucasian polypoidal choroidal vasculopathy
.
Br J Ophthalmol
.
2020
;
105
(
12
):
1716
23
.
10.
Cheung
CMG
,
Lai
TYY
,
Teo
K
,
Ruamviboonsuk
,
P
,
Chen
,
SJ
,
Kim
,
JE
, et al
.
Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the asia-pacific ocular imaging society PCV workgroup
.
Ophthalmology
.
2021
;
128
(
3
):
443
52
.
11.
Kim
YH
,
Lee
B
,
Kang
E
,
Oh
J
.
Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy
.
Graefes Arch Clin Exp Ophthalmol
.
2021
;
259
:
1711
21
.
12.
Bo
Q
,
Zhang
M
,
Chen
J
,
Jia
H
,
Shen
M
,
Sun
M
, et al
.
Progression of polypoidal lesions associated with exudative recurrence in polypoidal choroidal vasculopathy
.
Ophthalmology
.
2023
;
130
(
2
):
167
78
.
13.
Kim
JH
,
Chang
YS
,
Kim
JW
,
Kim
CG
,
Lee
DW
.
Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy
.
Eye
.
2017
;
31
(
12
):
1678
84
.
14.
Toto
L
,
Ruggeri
ML
,
Evangelista
F
,
Viggiano
P
,
D'Aloisio
R
,
De Nicola
C
, et al
.
Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy
.
Eye
.
2023
;
37
(
6
):
1214
8
.
15.
Toto
L
,
Ruggeri
ML
,
Evangelista
F
,
Trivigno
C
,
D'Aloisio
R
,
De Nicola
C
, et al
.
Choroidal and retinal imaging biomarkers in different types of macular neovascularization
.
J Clin Med
.
2023
;
12
(
3
):
1140
.
16.
Luo
M
,
Zhao
X
,
Yang
J
,
Chen
Y
.
The association of polypoidal choroidal vasculopathy clinical phenotypes with previously reported genetic markers
.
Graefe’s Archive Clin Exp Ophthalmol
.
2020
;
258
(
6
):
1199
203
.
17.
Yannuzzi
LA
,
Sorenson
J
,
Spaide
RF
,
Lipson
B
.
Idiopathic polypoidal choroidal vasculopathy (IPCV)
.
Retina
.
1990
;
10
(
1
):
1
8
.
18.
Yannuzzi
LA
,
Ciardella
A
,
Spaide
RF
,
Rabb
M
,
Freund
KB
,
Orlock
DA
.
The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy
.
Arch Ophthalmol
.
1997
;
115
(
4
):
478
85
.
19.
Spaide
RF
,
Yannuzzi
LA
,
Slakter
J
,
Sorenson
J
,
Orlach
DA
.
Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy
.
Retina
.
1995
;
15
(
2
):
100
10
.
20.
Fenner
BJ
,
Cheung
CMG
,
Sim
SS
,
Lee
WK
,
Staurenghi
G
,
Lai
TYY
, et al
.
Evolving treatment paradigms for PCV
.
Eye
.
2021
;
36
(
2
):
257
65
.
21.
Xia
F
,
Xing
P
,
Zhang
H
,
Niu
T
,
Wang
Q
,
Hua
R
.
Factors influencing visual acuity in patients with active subfoveal circumscribed polypoidal choroidal vasculopathy and changes in imaging parameters
.
Diagnostics
.
2023
;
13
(
18
):
3017
7
.
22.
Liu
K
,
Lai
TYY
,
Chiang
SWY
,
Chan
,
VCK
,
Young
,
AL
,
Tam
,
POS
, et al
.
Gender specific association of a complement component 3 polymorphism with polypoidal choroidal vasculopathy
.
Sci Rep
.
2014
;
4
(
1
):
7018
,
23.
Airaldi
M
,
Invernizzi
A
,
Nguyen
V
,
Vujosevic
S
,
Ricci
F
,
Monaco
P
, et al
.
Twenty‐four‐month real‐life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians
.
Clin Exp Ophthalmol
.
2023
;
51
(
8
):
799
807
.
24.
Cheung
CMG
,
Lee
WK
,
Koizumi
H
,
Dansingani
K
,
Lai
TYY
,
Freund
KB
.
Pachychoroid disease
.
Eye
.
2019
;
33
(
1
):
14
33
.
25.
Gupta
P
,
Ting
DSW
,
Thakku
SG
,
Wong
TY
,
Cheng
CY
,
Wong
E
, et al
.
Detailed characterization of choroidal morphologic and vascular features in age-related macular degeneration and polypoidal choroidal vasculopathy
.
Retina
.
2017
;
37
(
12
):
2269
80
.
26.
Cheung
CMG
.
Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management
.
Eye
.
2023
;
38
(
4
):
659
67
.
27.
Toto
L
,
Ruggeri
ML
,
D’Aloisio
R
,
De Nicola
C
,
Trivigno
C
,
Cerino
L
, et al
.
Brolucizumab intravitreal injection in macular neovascularization type 1: VA, SD-OCT and OCTA parameters changes during a 16-weeks follow up
.
Ophthalmic Res
.
2023
;
66
(
1
):
218
27
.
28.
Wakatsuki
Y
,
Shinojima
A
,
Kawamura
A
,
Yuzawa
M
.
Correlation of aging and segmental choroidal thickness measurement using swept source optical coherence tomography in healthy eyes
.
PLoS One
.
2015
;
10
(
12
):
e0144156
.
29.
Cheung
MG
,
Tan
CS
,
Patalauskaite
R
,
Margaron
P
,
Lai
TYY
.
Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
.
Retina
.
2020
;
41
(
2
):
387
92
.
You do not currently have access to this content.